Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients
International Clinical Psychopharmacology. 2011-09-01; 26(5): 252-262
Lire sur PubMed
1. Int Clin Psychopharmacol. 2011 Sep;26(5):252-62. doi:
Comparison of agomelatine and escitalopram on nighttime sleep and daytime
condition and efficacy in major depressive disorder patients.
Quera-Salva MA(1), Hajak G, Philip P, Montplaisir J, Keufer-Le Gall S, Laredo J,
(1)AP-HP Sleep Unit, Department of Physiology, Raymond Poincaré Hospital,
Agomelatine, an MT1/MT2 receptor agonist and 5-HT2C receptor antagonist
antidepressant, is known to have beneficial effects on subjective sleep in major
depressive disorder patients. This international multicenter, randomized,
double-blind study compared the effects of agomelatine (25-50 mg/day) and
escitalopram (10-20 mg/day) on sleep polysomnographic parameters in major
depressive disorder patients treated up to 24 weeks. A total of 138 outpatients
were randomly allocated to agomelatine (n=71) or escitalopram (n=67). Treatment
with agomelatine was associated with a reduction in sleep latency from week 2
onward. The difference between treatments was significant on all evaluations.
Rapid eye movement latency was increased with escitalopram compared with
agomelatine, with significant between-group differences at every visit.
Agomelatine preserved the number of sleep cycles, whereas it was decreased with
escitalopram with significant between-group differences at every visit.
Assessments on visual analogue scales indicated that treatment with agomelatine
improved morning condition, and reduced daytime sleepiness compared with
escitalopram.17-item Hamilton depression rating scale total score was reduced in
both groups, agomelatine was statistically noninferior to escitalopram at 6
weeks. Both treatments were well tolerated. This study showed that the clinical
effects of agomelatine on sleep and wake parameters are different from that of
PMID: 21829106 [Indexed for MEDLINE]